Cutera (CUTR) Set to Announce Quarterly Earnings on Thursday

Cutera (NASDAQ:CUTR) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter. Cutera has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Cutera (NASDAQ:CUTR) last issued its quarterly earnings results on Thursday, March 21st. The medical device company reported ($2.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($1.07). The firm had revenue of $49.54 million for the quarter, compared to the consensus estimate of $49.10 million. On average, analysts expect Cutera to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cutera Trading Down 3.8 %

Shares of Cutera stock opened at $2.75 on Wednesday. The company has a 50 day moving average of $1.98 and a 200-day moving average of $2.52. Cutera has a 1-year low of $1.28 and a 1-year high of $21.41. The company has a market cap of $54.85 million, a PE ratio of -0.37 and a beta of 1.43.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CUTR shares. Stephens reaffirmed an “overweight” rating and set a $10.00 price target on shares of Cutera in a report on Friday, March 22nd. William Blair raised shares of Cutera from an “underperform” rating to a “market perform” rating in a research note on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $14.75.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.